ECSP12012031A - Composición farmacéutica que comprende oligopéptidos - Google Patents

Composición farmacéutica que comprende oligopéptidos

Info

Publication number
ECSP12012031A
ECSP12012031A ECSP12012031A ECSP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A EC SP12012031 A ECSP12012031 A EC SP12012031A
Authority
EC
Ecuador
Prior art keywords
pharmaceutical composition
oligopeptides
includes oligopeptides
lipophilic
amphiphilic
Prior art date
Application number
Other languages
English (en)
Inventor
Marcus Eber
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44145957&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP12012031(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ECSP12012031A publication Critical patent/ECSP12012031A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica de oligopéptidos, con preferencia oligopéptidos cíclicos, en donde dicha composición también comprende uno o varios compuestos lipofílicos y/o anfifílicos, en presencia o ausencia de agua como los ingredientes principales, al uso de los compuestos lipofílicos y/o anfifílicos para preparar composiciones farmacéuticas de dichos oligopéptidos y a métodos de preparación de tal composición farmacéutica.
ECSP12012031 2009-12-10 2012-07-09 Composición farmacéutica que comprende oligopéptidos ECSP12012031A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28531309P 2009-12-10 2009-12-10
US41662810P 2010-11-23 2010-11-23

Publications (1)

Publication Number Publication Date
ECSP12012031A true ECSP12012031A (es) 2012-08-31

Family

ID=44145957

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSP12012031 ECSP12012031A (es) 2009-12-10 2012-07-09 Composición farmacéutica que comprende oligopéptidos

Country Status (20)

Country Link
US (1) US9433577B2 (es)
EP (1) EP2509583B1 (es)
JP (1) JP5946770B2 (es)
KR (1) KR20120104316A (es)
CN (1) CN102652015B (es)
AU (1) AU2010330364B2 (es)
BR (1) BR112012012862A2 (es)
CA (1) CA2783732A1 (es)
CL (1) CL2012001310A1 (es)
EA (1) EA022700B1 (es)
EC (1) ECSP12012031A (es)
ES (1) ES2742263T3 (es)
IL (1) IL220097A (es)
MX (1) MX2012006450A (es)
NZ (1) NZ601109A (es)
PE (1) PE20121359A1 (es)
PH (1) PH12012500754A1 (es)
SG (1) SG181487A1 (es)
WO (1) WO2011069629A2 (es)
ZA (1) ZA201205103B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3085704A1 (en) * 2009-05-20 2016-10-26 Merck Patent GmbH Novel solid materials of {[(2s, 5r, 8s, 11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them
EP2569633B1 (en) 2010-05-14 2016-02-10 The General Hospital Corporation Compositions and methods of identifying tumor specific neoantigens
EP2717854B1 (en) 2011-06-09 2019-01-16 Merck Patent GmbH Treatment of cancers and metastases with suspensions of cilengitide in carrier
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
WO2015085147A1 (en) 2013-12-05 2015-06-11 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
KR20230076867A (ko) 2013-12-20 2023-05-31 더 브로드 인스티튜트, 인코퍼레이티드 신생항원 백신과의 병용 요법
US10975442B2 (en) 2014-12-19 2021-04-13 Massachusetts Institute Of Technology Molecular biomarkers for cancer immunotherapy
EP3234130B1 (en) 2014-12-19 2020-11-25 The Broad Institute, Inc. Methods for profiling the t-cell- receptor repertoire
IL294183B2 (en) 2015-05-20 2023-10-01 Dana Farber Cancer Inst Inc shared neoantigens
US11549149B2 (en) 2017-01-24 2023-01-10 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
CA3058807A1 (en) 2017-04-03 2018-10-11 Biontech Us Inc. Protein antigens and uses thereof
KR102665710B1 (ko) 2017-08-24 2024-05-14 노보 노르디스크 에이/에스 Glp-1 조성물 및 그 용도
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
MX2020014243A (es) 2018-06-19 2021-05-12 Biontech Us Inc Neoantigenos y usos de los mismos.
JP7761567B2 (ja) 2020-02-18 2025-10-28 ノヴォ ノルディスク アー/エス 医薬製剤
US12531162B1 (en) * 2023-05-31 2026-01-20 Northeastern University Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
US12562256B2 (en) * 2023-11-07 2026-02-24 New York University Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668509B2 (en) * 1991-04-19 1996-05-09 Affinity Biotech, Inc. Convertible microemulsion formulations
AU667483B2 (en) 1991-07-26 1996-03-28 Smithkline Beecham Corporation W/O microemulsions
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
WO1998007414A1 (en) * 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
UA71608C2 (en) 1999-03-11 2004-12-15 Merck Patent Gmbh A method for producing the cyclic pentapeptide
IL160761A0 (en) 2001-10-19 2004-08-31 Isotechnika Inc Novel cyclosporin analog microemulsion preconcentrates
US6656460B2 (en) * 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
CA2524538A1 (en) 2003-05-19 2004-12-02 Baxter International Inc. Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers
DE602005010424D1 (de) * 2004-06-03 2008-11-27 Bracco Research Sa Liposomale anordnung für die therapeutische und/oder diagnostische anwendung
WO2009033730A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratoires Ag Peptide gxgrgdspca as a therapeutic agent
CN101990425B (zh) * 2008-04-08 2016-01-20 默克专利股份有限公司 包含环肽的组合物和使用方法
EP3085704A1 (en) * 2009-05-20 2016-10-26 Merck Patent GmbH Novel solid materials of {[(2s, 5r, 8s, 11s)-5-benzyl-11-(3-guanidino-propyl)-8-isopropyl-7-methyl-3,6,9,12,15-pentaoxo-1,4,7,10,13-pentaaza-cyclopentadec-2-yl]-acetic acid} and methods for obtaining them

Also Published As

Publication number Publication date
JP5946770B2 (ja) 2016-07-06
US20120288539A1 (en) 2012-11-15
WO2011069629A3 (en) 2012-03-15
PE20121359A1 (es) 2012-10-15
NZ601109A (en) 2014-06-27
US9433577B2 (en) 2016-09-06
CA2783732A1 (en) 2011-06-16
AU2010330364A1 (en) 2012-07-26
WO2011069629A2 (en) 2011-06-16
CN102652015B (zh) 2016-08-03
EP2509583A2 (en) 2012-10-17
ES2742263T3 (es) 2020-02-13
MX2012006450A (es) 2012-06-28
CN102652015A (zh) 2012-08-29
KR20120104316A (ko) 2012-09-20
EP2509583B1 (en) 2019-05-15
SG181487A1 (en) 2012-07-30
CL2012001310A1 (es) 2012-10-12
AU2010330364B2 (en) 2016-05-19
EA022700B1 (ru) 2016-02-29
BR112012012862A2 (pt) 2016-08-16
ZA201205103B (en) 2013-03-27
JP2013513556A (ja) 2013-04-22
EA201200850A1 (ru) 2013-01-30
IL220097A (en) 2017-03-30
PH12012500754A1 (en) 2018-03-21

Similar Documents

Publication Publication Date Title
ECSP12012031A (es) Composición farmacéutica que comprende oligopéptidos
GT201400136A (es) Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos
ECSP12011939A (es) Compuestos Lipopéptidos y métodos relacionados
UY32728A (es) Composición farmacéutica y procedimiento de tratamiento para la anticoncepción de emergencia
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
ECSP12011935A (es) Triazolopiridinas
MX2013003365A (es) Composicion farmaceutica.
GT201200334A (es) Morfolinopirimidinas y su uso en terapia
CO6650348A2 (es) Triazolopiridinas sustituidas
DOP2014000133A (es) Triazolopiridinas sustituidas
ECSP13013011A (es) Triazolopiridinas
MX2012008717A (es) Composiciones para el cuidado oral.
CL2012000508A1 (es) Composicion para la aplicacion en cultivos agricolas al aire libre o invernaderos que comprende zeolita, y aditivos; uso de la composicion para aumentar el rendimiento de los cultivos agricolas.
CR20120357A (es) Composición que comprende un pesticida y un alcoxilato de 2-propilheptilamina
CO6640301A2 (es) Compuestos ologo-benzamida y su uso
CL2013001945A1 (es) Compuestos derivados de pirazol de fórmulas (ia) o (ib), antagonistas de crth2; composiciones farmaceuticas que los contienen; combinaciones farmaceuticas; su uso en la prevencion y/o el tratamiento de trastornos inflamatorios, infecciosos e inmunorreguladores.
CL2012003265A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de enfermedades infecciosas; composicion farmacéutica y/o dermocosmética antiinflamatoria que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo.
AR075228A1 (es) Composiciones para el tratamiento del cabello.
NZ610950A (en) Pharmaceutical compositions comprising alisporivir
IT1398875B1 (it) Composizioni contenti l. mucosae per uso medico.
CL2012001759A1 (es) Compuestos derivados de 8-hidroxiquinolina-7-carboxamida; composicion farmaceutica.
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
MX2012007172A (es) Piperazinas como agentes antimalaria.
CO6501127A2 (es) Composiciones farmacéuticas que comprende oligopeptidos
BR112013004981A2 (pt) composição líquida